公司方面表示尚未找到接替人选，为保证公司财务工作的正常开展，在董事会聘任新的财务总监之前，暂由公司董事长赵守明先生代行财务总监职责。①Tonight, wanbangde announced that the Chief Financial Officer Wang Tianfang resigned after only 8 months in office; ② Chairman Zhao Shouming once again assumed the responsibilities of the Chief Financial Officer. In June 2022, he also acted for a period of time when the former CFO Zhao Junhui resigned; ③ Within three years, wanbangde's market cap has shrunk to only one-third.
On September 29, Financial Zhang 疸社 (reporter Lu Afeng) announced that the Chief Financial Officer who served for only eight months resigned, and wanbangde (002082.SZ) announced that it will be temporarily taken over by Chairman Zhao Shouming as the Chief Financial Officer.
On the evening of September 29, wanbangde issued an announcement stating that the company's board of directors recently received a written resignation report from Director and CFO Wang Tianfang. Due to personal reasons, Wang Tianfang has requested to resign from the position of director and CFO of the Ninth Board of Directors of the company. After resigning from the above positions, Wang Tianfang will not hold any other positions within the company.
The company indicated that a replacement has not yet been found. To ensure the normal operation of the company's financial work, before appointing a new CFO, it will be temporarily assumed by Chairman Zhao Shouming.
Public information shows that wanbangde's subsidiary, wanbangde Pharmaceutical Group, is a high-tech enterprise specializing in the research and development, production, and sales of modern traditional Chinese medicine, active pharmaceutical ingredients, and preparations. It has the production capacity of 14 dosage forms including pellets, tablets, capsules, granules, oral liquid, small-volume injections, large-volume injections, as well as chemical raw materials and traditional Chinese medicine extracts, making it one of the domestic pharmaceutical companies with a wide range of pharmaceutical dosage forms.
According to wanbangde's previous announcements, Wang Tianfang was born in June 1962, is nearly 62 years old, holds an associate degree, is a registered accountant, and a senior accountant. He has served as the Finance Department Manager of Zhejiang Wanbang Pharmaceutical Co., Ltd., the CFO of wanbangde Pharmaceutical Group Co., Ltd., and is currently the CFO of wanbangde Pharmaceutical Group Co., Ltd., as well as a Director and CFO of wanbangde Medical Holding Group Co., Ltd.
In fact, Wang Tianfang's tenure as CFO and director was not long. In June 2022, the company's former director and CFO, Zhao Junhui, resigned, and Chairman Zhao Shouming temporarily assumed the role of CFO for a period of time. On July 28, 2023, Wang Tianfang became a director of wanbangde, and in January of this year, he was promoted to CFO until today's announcement of his resignation, serving in that position for about 8 months.
On the performance side, wanbangde's revenue decreased by 13.69% year-on-year last year, its net income attributable to shareholders decreased by 47.23% year-on-year, and its non-GAAP net income decreased by 70.19% year-on-year; in the first half of 2024, wanbangde's revenue increased by 1.93% year-on-year, net income attributable to shareholders increased by 19.36% year-on-year, but non-GAAP net income decreased by 4.53% year-on-year.
It is worth noting that in January 2022, five months before Zhao Junhui resigned, Wanbangde's stock price hit a nearly three-year high record. However, from then until September 27th of this year, Wanbangde's market cap has evaporated by more than two-thirds, with a total market cap of 2.806 billion yuan.
